Aclara, ViroLogic deal

VLGC will merge with ACLA to form a personalized medicine company focused on cancer and infectious diseases. VLGC will own 52% of the merged entity, and ACLA will own 48%. The deal combines VLGC’s commercial laboratory and patient testing with ACLA’s eTag System for molecular assay development. The combined company plans to develop cancer tests based on the eTag technology. VLGC also will contribute its marketed HIV resistance assays, which include PhenoSense GT and PhenoSense HIV. ACLA said that the merger will improve the time to market for eTag products, because ACLA will not have to develop commercial infrastructure. ...